Search For "gamaleya center"
Russia develops Delta & Omicron-adapted Sputnik V vaccine
Updated : 3 years, 6 months ago IST
Moscow [Russia], August 23 (ANI): Russia's Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund announced the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.
Read More
Sputnik V demonstrates high virus neutralizing activity against Omicron: S
Updated : 4 years, 2 months ago IST
Moscow [Russia], December 22 (ANI): Sputnik V demonstrates high virus-neutralizing activity against Omicron variant, according to a study by Gamaleya Center's preliminary laboratory.
Read More
Putin offers to partake in testing of Russian nasal vaccine against COVID-
Updated : 4 years, 3 months ago IST
Moscow [Russia], November 22 (ANI/Sputnik): Russian President Vladimir Putin has offered to become a volunteer in the testing of the Russian candidate nasal vaccine against COVID-19 during a meeting with Denis Logunov, deputy head of the Gamaleya Center, on Sunday.
Read More
Russia's Sputnik Light vaccine is 70 pc effective against Delta variant of
Updated : 4 years, 5 months ago IST
Moscow [Russia], October 13 (ANI): Sputnik Light, Russia's single-dose COVID-19 vaccine, has been found to demonstrate 70 per cent efficacy against infection with the Delta variant during the first three months after vaccination.
Read More
Sputnik Light has proven to be 'ideal booster' for other vaccines
Updated : 4 years, 5 months ago IST
Moscow [Russia], October 8 (ANI): Russian Direct Investment Fund on Thursday said that coronavirus vaccine Sputnik Light has proven to be an ideal booster for other vaccines and is ready to fight the COVID-19 globally.
Read More
Sputnik V vaccine efficacy confirmed at '91.4 per cent' during Phase 3 tri
Updated : 5 years, 3 months ago IST
Moscow [Russia], December 14 (ANI): The efficacy of the Sputnik V COVID-19 vaccine has been confirmed to be 91.4 per cent, based on data analysis of the final control point of clinical trials, announced the Gamaleya National Center of Epidemiology and Microbiology and the Russian Direct I
Read More